16 hrs ago | Lawyers Weekly USA
Pfizer jury said to award $75M Prempro verdict
Pfizer Inc. must pay about $75 million in punitive damages to an Illinois woman who developed cancer after taking one of the drugmakera s menopause treatments, people familiar with a sealed verdict in the case said.
Linklaters' Schmidt on Pfizer-Wyeth review
The approval by U.S. antitrust regulators of Pfizer Inc.'s acquisition of Wyeth is an outlier of how merger reviews will be conducted under the Obama administration.
Dutch pull Pfizer vaccine batch after infants die
Dutch authorities say they have banned use of a batch of Pfizer's Prevenar, or Prevnar, after three infants died within two weeks of receiving the anti-infection vaccination.
Significantly More Smokers With Mild-To-Moderate COPD Quit...
Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX Compared With Placebo Main Category: Smoking / Quit Smoking Also Included In: Respiratory / Asthma ; COPD Article Date: 05 Nov 2009 - 13:00 PST New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease ...
Moody's upgrades ratings for Wyeth
Moody's Investors Service upgraded the senior unsecured ratings of Wyeth, citing the execution of an outstanding bonds agreement with Wyeth.
Merck, Now No. 2 Drugmaker, Set for Future Buys
The new Merck & Co . has become the world's second-biggest drugmaker overnight with a huge acquisition, but it still has a fat wallet and plans more wheeling and dealing.
Merck, now No. 2, set for future buys
The new Merck & Co. has become the world's second-biggest drugmaker overnight, with a fat wallet to fund future deals.
Flamel Technologies Announces Licensing Agreement with Pfizer Inc.
Flamel Technologies today announced that Pfizer has exercised its option to license Flamela s MedusaA technology for the development of a controlled release formulation of an already-marketed therapeutic protein.
Pfizer and Glaxo launch HIV company ViiV Healthcare
Drugmakers Pfizer Inc. and GlaxoSmithKline today launched a new, independent company specializing in HIV treatments, naming it ViiV Healthcare with worldwide headquarters in London.
Merck, Schering-Plough set to complete merger
Merck & Co and Schering-Plough Corp said their $41.1 billion merger will be completed later on Tuesday, marking the close of the second huge deal in the pharmaceutical industry in recent weeks.
www.PicksThatMove.com: "Picks that move" Alerts, November 03, 2009: NAL, WIN, DOW, PFE, SWI and HNT
Picksthatmove.com Alerts include NewAlliance Bancshares, Inc. ; Windstream Corporation ; The Dow Chemical Company ; Pfizer Inc ; SolarWinds and Health Net, Inc.
FDA won't accept Merck's application for new drug
U.S. regulators won't accept drugmaker Merck's application for a new combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug.
Hedge Funds: Einhorn gained almost 4% in October
David Einhorn generated gains of almost 4% in October, according to the investment results of Greenlight Capital Re, a reinsurer that invests its premiums with the hedge fund manager.
Colorado Springs Business Journal
Pharm companies pay up to settle marketing-scheme allegations
Four pharmaceutical manufacturers have paid the state $3 million to settle claims they improperly marketed drugs and paid kickbacks to health care professionals in return for prescribing their products.
Complimentary Research Report on CA, MMR, PFE, WEC, NXG and WNR by WallStSense.com
Our analysts have issued complimentary analysis on the following six companies: CA Inc.
Pfizer open to settlement with Unilab
Multinational drug giant Pfizer Inc. has expressed willingness to settle amicably with United Laboratories Inc.
Pfizer lets shareholders weigh in on exec pay
Pfizer Inc.'s board of directors has agreed to listen to shareholders' views about executive compensation.
World's Scariest Stocks: Pfizer
In this series, you'll find companies with scary valuations, scary prospects for growth, and financial stocks with scary volatility.
BYU awarded $852K in ongoing lawsuit with Pfizer
A federal magistrate has awarded Brigham Young University more than $852,000 in attorney fees and other costs in an ongoing lawsuit between the school and drugmaker Pfizer Inc.
Pfizer shareholders to get vote on executive pay
Drugmaker Pfizer Inc. said Thursday its shareholders will have input on compensation for company executives starting in 2010.
Also on Topix